---
title: "Nkarta 宣佈將在即將舉行的美國風濕病學會（ACR）匯聚會議上進行海報展示"
description: "南舊金山，加利福尼亞州，2025 年 10 月 22 日（GLOBE NEWSWIRE）-- Nkarta, Inc.（納斯達克股票代碼：NKTX），一家臨牀階段的生物製藥公司，正在開發工程化自然殺傷（NK）細胞療法以治療自身免疫疾病，今天宣佈將於本週日於芝加哥展示一份海報……"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262270942.md"
published_at: "2025-10-22T14:38:56.000Z"
---

# Nkarta 宣佈將在即將舉行的美國風濕病學會（ACR）匯聚會議上進行海報展示

> 南舊金山，加利福尼亞州，2025 年 10 月 22 日（GLOBE NEWSWIRE）-- Nkarta, Inc.（納斯達克股票代碼：NKTX），一家臨牀階段的生物製藥公司，正在開發工程化自然殺傷（NK）細胞療法以治療自身免疫疾病，今天宣佈將於本週日於芝加哥展示一份海報……

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( NASDAQ:NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago ...

### Related Stocks

- [NKTX.US - Nkarta](https://longbridge.com/zh-HK/quote/NKTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nkarta Unveils Promising NKX019 Data for B-Cell Depletion in Autoimmune Disease Models | Nkarta Inc. announced it will present new clinical data on its investigational therapy, NKX019, at the ACR Convergence 2 | [Link](https://longbridge.com/zh-HK/news/262267264.md) |
| FY2025 Earnings Estimate for Nkarta Issued By William Blair | William Blair raised Nkarta's FY2025 EPS estimate to ($1.36) from ($1.38). The consensus full-year EPS is ($1.70). FY202 | [Link](https://longbridge.com/zh-HK/news/265940201.md) |
| Is Chemo‑Free NK Regimen and Global ANKTIVA Push Altering The Investment Case For ImmunityBio (IBRX)? | ImmunityBio has launched the ResQ215B Phase 2 trial for a chemotherapy-free NK-cell regimen, ANKTIVA, in treating indole | [Link](https://longbridge.com/zh-HK/news/276002096.md) |
| 07:24 ETSobi to host a Capital Markets Day on 18 February 2026 | Swedish Orphan Biovitrum AB (Sobi) will host a Capital Markets Day on 18 February 2026, in Stockholm, starting at 13:00  | [Link](https://longbridge.com/zh-HK/news/275604106.md) |
| Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | [Link](https://longbridge.com/zh-HK/news/275926557.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。